Strateos, a Menlo Park, CA-based company which specializes in development of remote access laboratories and lab control software for life science research, raised $56.1M in Series B funding.
The round was led by DCVC and Lux Capital with participation from new investors including Eli Lilly and Company, Ally Bridge Group, Black Diamond Ventures, Mack & Co., LLC, and Castor Ventures.
The company intends to use the funds to continue to develop its solutions.
Led by Mark Fischer-Colbrie, CEO, Strateos provides SmartLab Platform™, which integrates data generation and AI-enablement with its automation capabilities to accelerate pharmaceutical and synthetic biology R&D.
Strateos leverages the resources of the company’s two SmartLab Studios in Menlo Park and San Diego, California, which together represent more than 14,000 square feet of laboratory space and 200-plus research instruments tailored to the application needs of small-molecule and biologics drug discovery, cell and gene therapies and synthetic biology. These remote-controlled, secure labs are accessed through command-and-control tools that enable scientists to design, manage, and collaborate on scientific workflows that deliver high-quality data that can be readily analyzed and shared. Strateos’ life sciences customers are also leveraging the Command & Control software to improve their internal operations and laboratory facilities locally, and worldwide.